- Micro cap Aveo Pharmaceuticals (NASDAQ:AVEO) is up 31% premarket on robust volume as investors continue to pile in after a presentation at ASCO two days ago of positive data on its lead product candidate, tivozanib, in kidney cancer.
- Shares have almost tripled since mid-May.
- Previously: Aveo up on positive tivozanib data; shares up 17% premarket (June 2)